Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2

Neuro-Oncology

Volumn 13, Issue 7, 2011, Pages 759-766

  Ammoun, Sylwia ^a   Schmid, Marei Caroline ^a   Triner, Joceline ^a   Manley, Paul ^b   Hanemann, Clemens Oliver ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Imatinib nilotinib selumetinib; Merlin; PDGFR b ERK AKT; Proliferation; Schwannoma

Indexed keywords

IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; NILOTINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SELUMETINIB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; NEURILEMOMA; NEUROFIBROMATOSIS; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOBLOTTING; MAP KINASE SIGNALING SYSTEM; NEURILEMMOMA; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 80052726645     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor056     Document Type: Article

References (26)

1. Hanemann CO. Magic but treatable? Tumours due to loss of merlin. Brain. 2008;131:606-615.
2. Hanemann CO, Evans DG. News on the genetics, epidemiology, medical care and translational research of Schwannomas. J Neurol. 2006;253:1533-1541. (Pubitemid 46115433)
3. Rosenbaum C, Kluwe L, Mautner VF, et al. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis. 1998;5:55-64. (Pubitemid 28361652)
4. Schulze KM, Hanemann CO, Muller HW, et al. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet. 2002;11: 69-76. (Pubitemid 34100769)
5. Ammoun S, Flaiz C, Ristic N, et al. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signalregulated kinase pathway in human schwannoma. Cancer Res. 2008;68:5236-5245.
6. Ammoun S, Ristic N, Matthies C, et al. Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244. Neurobiol Dis. 2010;37:141-146.
7. Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol. 2010;12:834-843.
8. Fraenzer JT, Pan H, Minimo L, Jr, et al. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol. 2003;23:1493-1500.
9. Waller CF. Imatinib mesylate. Recent Results Cancer Res. 2010;184:3-20.
10. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551. (Pubitemid 43882350)
11. Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008;30:1956-1975.
12. Utermark T, Kaempchen K, Antoniadis G, et al. Reduced apoptosis rates in human schwannomas. Brain Pathol. 2005;15:17-22. (Pubitemid 40224062)
13. Kaempchen K, Mielke K, Utermark T, et al. Upregulation of the Rac1/ JNK signaling pathway in primary human schwannoma cells. Hum MolGenet. 2003;12:1211-1221. (Pubitemid 36722601)
14. Hanemann CO, Bartelt-Kirbach B, Diebold R, et al. Differential gene expression between human schwannoma and control Schwann cells. Neuropathol Appl Neurobiol. 2006;32:605-614. (Pubitemid 44684646)
15. Pirraco A, Coelho P, Rocha A, et al. Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells. J Cell Biochem. 2010;111:433-441.
16. Biswas SK, Zhao Y, Sandirasegarane L. Imatinib induces apoptosis by inhibiting. Mol Vis. 2009;15:1599-1610.
17. Zhang J, Adrian FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010;463:501-506.
18. Mukherjee J, Kamnasaran D, Balasubramaniam A, et al. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). Cancer Res. 2009;69:5099-5107.
19. Lepont P, Stickney JT, Foster LA, et al. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mutat Res. 2008;637:142-151. (Pubitemid 350256772)
20. Wright JA, Huang A. Growth factors in mechanisms of malignancy: roles for TGF-beta and FGF. Histol Histopathol. 1996;11:521-536. (Pubitemid 26135212)
21. Tanaka C, Yin OQ, Sethuraman V, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther. 2010;87:197-203.
22. Davies A, Jordanides NE, Giannoudis A, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009;23:1999-2006.
23. Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res. 2004;10:681-690. (Pubitemid 38174008)
24. Atanasoski S, Boentert M, De VL, et al. Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclindependent kinase 4 (cdk4). Mol Cell Neurosci. 2008;37:519-527.
25. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11:5472-5480. (Pubitemid 41060823)
26. Kang ES, Oh MA, Lee SA, et al. EGFR phosphorylation-dependent formation of cell-cell contacts by Ras/Erks cascade inhibition. Biochim Biophys Acta. 2007;1773:833-843.